Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up

Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up

Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare variant of HL that accounts for 5% of all HL cases. The expression of CD20 on neoplastic lymphocytes provides a suitable target for novel treatments based on Rituximab. Due to its rarity, consolidated and widely accepted t...

Full description

Bibliographic Details
Main Authors: Novella Pugliese, Marco Picardi, Roberta Della Pepa, Claudia Giordano, Francesco Muriano, Aldo Leone, Giuseppe Delle Cave, Alessandro D’Ambrosio, Violetta Marafioti, Maria Gabriella Rascato, Daniela Russo, Massimo Mascolo, Fabrizio Pane
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
nodular lymphocyte predominant hodgkin lymphoma
rituximab
progression-free survival
Online Access:https://www.mdpi.com/2072-6694/13/8/1760

Internet

https://www.mdpi.com/2072-6694/13/8/1760

Similar Items